Arcus Biosciences Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018	2017	2016
Net Income	-307	-267	53	-123	-84.71	-49.59	-53.08	-17.97
Depreciation & Amortization	16	14	7	4	3.58	3.66	2.61	1.31
Share-Based Compensation	73	65	55	22	8.98	3.87	0.5	0.09
Other Operating Activities	-88	626	-371	208	-1.31	-0.94	24.92	3.62
Operating Cash Flow	-306	438	-256	111	-73.46	-43	-25.06	-12.94
Capital Expenditures	-24	-6	-26	-3	-1.93	-3.74	-5.51	-4.1
Acquisitions	0	-3	0	0	0	0	0	-1
Change in Investments	218	-404	22	-431	61.14	-109.7	-43.56	-33.76
Investing Cash Flow	194	-413	-4	-434	59.21	-113.44	-49.07	-38.86
Share Issuance / Repurchase	33	23	232	439	1.12	129.21	0.89	0.28
Other Financing Activities	-	10	5	-	-	-0.14	106.5	69.82
Financing Cash Flow	33	33	237	439	1.12	129.07	107.4	70.1
Net Cash Flow	-79	58	-23	116	-13.13	-27.36	33.27	18.3
Free Cash Flow	-330	432	-282	108	-75.39	-46.74	-30.57	-17.04
Free Cash Flow Margin	-282.05%	385.71%	-73.63%	138.46%	-502.58%	-559.55%	-2163.69%	-
Free Cash Flow Per Share	-4.46	6.00	-4.07	1.97	-1.72	-1.35	-16.72	-19.73

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).